Few cases of graft posttransplant lymphoproliferative disease (PTLD) in pulmonary transplant recipients have been reported. Published data on PTLD are pooled to analyze and compare characteristics, predictors, and prognosis of pulmonary PTLDs arising in lung allograft recipients.
Materials and Methods
PubMed and Google Scholar were searched for reports of lymphoproliferative disorders occurring within the graft in lung transplant recipients. Data from 23 studies were pooled and analyzed.
Results
Data from 137 patients (61 graft locations) with PTLD after lung transplantation were analyzed. Lung recipients with pulmonary graft PTLD were significantly more likely to have early-onset PTLD (70% vs 31%, respectively; P< .001). Lung graft PTLD also was associated with having tested negative for infection with Epstein-Barr virus before transplantation (P = .05). Log-rank test showed significantly higher survival rates for pulmonary transplant recipients with allograft complication than for recipients with PTLD elsewhere (P = .02).
Conclusion
Pulmonary transplant recipients who show early symptoms of impaired graft function should be evaluated for a potential lung graft PTLD in addition to being assessed for risk of rejection. Further prospective studies with large populations of patients are needed to confirm these results.
Get full access to this article
View all access options for this article.
References
1.
PennIHammondWBrettschneiderLStarzlTE. Malignant lymphomas in transplantation patients. Transplant Proc.1969; 1(1): 106–112.
2.
LevyMBackmanLHusbergB. De novo malignancy following liver transplantation: A single-center study. Transplant Proc.1993;25:1397–1399.
3.
NalesnikMAJaffeRStarzlTE. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol.1988;133(1): 173–192.
4.
KhedmatHTaheriS. Early onset post transplantation lymphoproliferative disorders: Analysis of international data from 5 studies. Ann Transplant.2009;14(3):74–77.
5.
KhedmatHTaheriS. Late onset post transplantation lymphoproliferative disorders: Analysis of international data from 5 studies. Ann Transplant.2009;14(4):80–85.
6.
KhedmatHAlavianSTaheriS. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant.2010;15(2):40–44.
7.
KhedmatHTaheriS. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey. Ann Transplant.2010;15(3):80–86.
8.
IzadiMTaheriS. Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: Report from the PTLD.Int Survey. Ann Transplant.2010;15(4):102–109.
9.
PourfarzianiVTaheriSLessan-PezeshkiM. Lymphoma after living donor kidney transplantation: An Iranian multicenter experience. Int Urol Nephrol.2008;40(4):1089–1094.
10.
NuckolsJDBaronPWStenzelTT. The pathology of liver-localized post-transplant lymphoproliferative disease: A report of three cases and a review of the literature. Am J Surg Pathol.2000;24(5):733–741.
11.
GreifFBronstherOLVan ThielDH. The incidence, timing and management of biliary tract complications after orthotopic liver transplantation. Ann Surg.1994;219(1):40–45.
12.
McDiarmidSVJordanSKimGS. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation.1998;66(12):1604–1611.
13.
PennI. De novo cancers in organ allograft recipients. Curr Opin Organ Transplant.1998;3:188–199.
14.
AngelLFCaiTHSakoEYLevineSM. Posttransplant lymphoproliferative disorders in lung transplant recipients: Clinical experience at a single center. Ann Transplant.2000;5(3):26–30.
15.
MontoneKTLitzkyLAWursterA. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery.1996; 119(5):544–551.
16.
DharnidharkaVRTejaniAHHoPLHarmonWE. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant.2002;2(10):993–998.
17.
RamalingamPRybickiLSmithMD. Posttransplant lymphoproliferative disorders in lung transplant patients: The Cleveland Clinic experience. Mod Pathol.2002;15(6):647–656.
18.
IzadiMTaheriS. Hepatic involvement by lymphoproliferative disorders post liver transplantation: Report from the PTLD.Int. Survey. Hepatol Int.http://www.springerlink.com/content/c635w17m53485812. Published March 30, 2011. Accessed October 3, 2011.
19.
ReaDFourcadeCLeblondV. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation.1994;58(3):317–324.
20.
KenagyDNSchlesingerYWeckK. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with post-transplant lymphoproliferative disease. Transplantation.1995;60(6):547–554.
21.
HachemRRChakinalaMMYusenRD. Abdominal-pelvic lymphoproliferative disease after lung transplantation: Presentation and outcome. Transplantation.2004;77(3):431–437.
22.
LucioniMIppolitiGCampanaC. EBV positive primary cutaneous CD30+ large T-cell lymphoma in a heart transplanted patient: Case report. Am J Transplant.2004;4(11):1915–1920.
23.
TrappeRRiessHBabelN. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. transplantation.2007;83(7):912–918.
24.
WildeGEMooreDJBellahRD. Posttransplantation lymphoproliferative disorder in pediatric recipients of solid organ transplants: Timing and location of disease. AJR Am J Roentgenol.2005;185(5):1335–1341.
ShitritDShitritABDickmanRSaharGSauteMKramerMR. Gastrointestinal involvement of posttransplant lymphoproliferative disorder in lung transplant recipients: Report of a case. Dis Colon Rectum.2005;48(11):2144–2147.
27.
LoevnerLAKarpatiRLKumarPYousemDMHsuWMontoneKT. Posttransplantation lymphoproliferative disorder of the head and neck: Imaging features in seven adults. Radiology.2000;216(2):363–369.
DavisJESherrittMABharadwajM. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol.2004; 16(7):983–989.
30.
DusenberyDNalesnikMALockerJSwerdlowSH. Cytologic features of post-transplant lymphoproliferative disorder. Diagn Cytopathol.1997;16(6):489–496.
31.
AllenUDFarkasGHebertD. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant.2005;9(4):450–455.
32.
HerrmannBWSweetSCMolterDW. Sinonasal posttransplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg.2005; 133(1):38–41.
33.
EladSMeyerowitzCShapiraMYGlickMBitanMAmirG. Oral posttransplantation lymphoproliferative disorder: An uncommon site for an uncommon disorder. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2008;105(1):59–64.
34.
ParanjothiSYusenRDKrausMDLynchJPPattersonGATrulockEP. Lymphoproliferative disease after lung transplantation: Comparison of presentation and outcome of early and late cases. J Heart Lung Transplant.2001;20(10):1054–1063.
35.
WoodBLSabathDBroudyVCRaghuG. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases. Cancer.1996;78(10):2223–2228.
36.
ReamsBDMcAdamsHPHowellDNSteeleMPDavisRDPalmerSM. Posttransplant lymphoproliferative disorder: Incidence, presentation, and response to treatment in lung transplant recipients. Chest.2003;124(4):1242–1249.
37.
KnoopCKentosARemmelinkM. Post-transplant lymphoproliferative disorders after lung transplantation: First-line treatment with rituximab may induce complete remission. Clin Transplant.2006;20(2):179–187.
38.
WigleDAChaparroCHumarAHutcheonMAChanCKKeshavjeeS. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation.2001;72(11):1783–1786.
39.
Diaz-GuzmanEFarverCKanneJPMehtaAC. A 65-year-old man with odynophagia and a lung mass. Chest.2009; 135(3): 876–879.
40.
LeePMinaiOAMehtaACDeCampMMMurthyS. Pulmonary nodules in lung transplant recipients: Etiology and outcome. Chest.2004;125(1):165–172.
41.
KhedmatHTaheriS. Heart allograft involvement by post-transplant lymphoproliferative disorders: Report from the PTLD.Int survey. Exp Clin Transplant.2011;9(4):258–264.
42.
AliMGCoakleyFVHricakH. Complex posttransplantation abnormalities of renal allografts: Evaluation with MR imaging. Radiology.1999;211(1):95–100.
43.
GhobrialIMHabermannTMMaurerMJ. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol.2005;23(30):7574–7582.
44.
CockfieldSM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis.2001;3(2): 70–78.
45.
HantoDWFrizzeraGPurtiloDT. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res.1981;41(11 pt 1):4253–4261.
46.
HantoDWFrizzeraGGajl-PeczalskaKJ. Epstein-Barr virus induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med.1982;306(15):913–918.
47.
WhelessSAGulleyMLRaab-TraubN. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med.2008;178(10):1060–1065.
48.
SasaharaYKawaiSItanoM. Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol.1998;15(4):347–352.
49.
ShapiroRSMcClainKFrizzeraG. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood.1988;71(5):1234–1243.
50.
MentzerSJLongtineJFingerothJ. Immunoblastic lymphoma of donor origin in the allograft after lung transplantation. Transplantation.1996;61(12):1720–1725.
51.
WeissmannDJFerryJAHarrisNLLouisDNDelmonicoFSpiroI. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol.1995;103(6):748–755.
